Otsuka to leverage strong commercial infrastructure and rare disease experience to reach European HAE patients Ionis plans to independently bring donidalorsen to U.S. patients if approved Donidalorsen Phase 3 results expected in the first half of 2024 CARLSBAD, Calif. , Dec.
Read more